TrialClinical lymphoma, myeloma & leukemia2015

A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Ryan D Cassaday et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.